-
A total of 183 (55.29%, 183/331) strains were classified into Beijing family with a single point mutation in the Rv2952 gene, and 148 (44.71%, 148/331) non-Beijing family strains without a single point mutation in Rv2952 were defined (Table 1). Following the 8 SNPs based on the 3R genes, the Beijing family strains were grouped into eight sub-lineages (Table 1). The most predominant sub-lineage was Bmyc10 (39.34%, 72/183), followed by Bmyc25 (20.77%, 38/183), Bmyc210 (17.49%, 32/183), Bmyc2 (5.46%, 10/183) and Bmyc4 (5.46%, 10/183), Bmyc26 (4.37%, 8/183), Bmyc13 (3.83%, 7/183) and Bmyc6 (3.78%, 6/183). Among all the sub-lineages, Bmyc10, Bmyc13, and Bmyc210 were defined as modern Beijing strains (60.66%, 111/183) according to the mutation of mutT2_58 gene[32]. Strains without mutations were defined as ancient Beijing strains. Bmyc10 and Bmyc25 were the most prevalence sub-lineage of modern and ancient Beijing strains, respectively.
Table 1. Distribution of 183 Beijing Strains in Each Sub-lineage (W = wildtype, M = mutant)
Sublineage SNPs No. (%) Subgroup recR (codon 44) mutT4 (codon 48) recX (codon 59) mutT2 (codon 58) uvrD1 (codon 462) adhE2 (codon 124) ligD (codon 580) ogt (codon 37) Bmyc2 W W W W W W M W 10 (5.46) Ancient Bmyc4 M W W W W W W W 10 (5.46) Ancient Bmyc6 M M W W W W W W 6 (3.78) Ancient Bmyc25 M M W W W W W M 38 (20.77) Ancient Bmyc26 M M M W W W W W 8 (4.37) Ancient Bmyc10 M M M M W W W W 72 (39.34) Modern Bmyc13 M M M M M W W W 7 (3.83) Modern Bmyc210 M M M M W M W W 32 (17.49) Modern -
We performed 15-loci VNTR to all 331 isolates to study the transmission clusters and population diversity of MTB in remote mountainous areas of southwest China. two hundred sixty-one MTB strains (78.61%; 261/331) had complete VNTR genotyping data that were included in this study. The 261 isolates were classified into 15 clusters (2 to 5 strains per cluster) and 224 unique genotypes, showing a clustering rate of 14.18% (37/261) and a discriminatory index of 0.9990 (Figure 2). The 148 Beijing isolates and 113 non-Beijing strains both contained 7 clusters. In addition, we also calculated the HGI for Beijing lineage and non-Beijing lineage. The Beijing family contained 129 unique genotypes, showing a clustering rate of 12.84% (19/148) and a discriminatory index of 0.9981. Additionally, the non-Beijing family isolates showed a clustering rate of 14.16% (16/113) and a discriminatory index of 0.9983. No significant difference between the Beijing and non-Beijing strains was observed with respect to the clustering rate (χ2 = 0.096, P = 0.756). There is a trend toward higher resolution for Beijing strains compared with non-Beijing strains (0.9983 vs. 0.9981); however, the trend was not significant. From the minimal spanning tree of the 261 strains based on VNTR-15 data, Beijing strains were mainly concentrated in one complex (shadowed with red color), and the genetic distance was relatively close, and non-Beijing strains were more dispersed (Figure 2). There were three isolates that were defined as non-Beijing strains (marked with fluorescent green color) located on the Beijing strains complex (Figure 2).
Figure 2. Minimal spanning tree of the 261 strains based on VNTR data. Each circle corresponds to a certain VNTR type. The size of the circle is proportional to the number of the isolates. The shadow zones in different colors correspond to different clonal complexes, and the color within the cycles represents different sub-lineages. The dotted line separates Beijing and non-Beijing strains.
-
Among all 331 clinical strains, 19.64% (65/331) isolates were resistant to any drugs involved in this study. The resistance rates from high-to-low were INH (10.57%), SM (9.97%), OFX (8.16%), RFP (5.44%), PAS (3.32%), KAM (2.11%), CPM (1.81%), EMB (1.21%), and PTO (0.30%). Seventeen [4.98% (17/331)] MTB isolates were detected as MDR-TB, and of these, 15 [88.24% (15/17)] were Beijing family MTB, and 2 [11.76% (2/17)] were non-Beijing strains (Table 2). Beijing strains had significantly higher rates of resistance to INH (χ2 = 5.715, P = 0.017) and RFP (χ2 = 6.057, P = 0.014; Table 2) compared with non-Beijing strains. Extremely significant differences were observed regarding PAS resistance (χ2 = 7.426, P = 0.006) and MDR (simultaneous INH and RFP resistance; χ2 = 7.870, P = 0.005) between the Beijing strains and non-Beijing strains (Table 2); however, there was no significant difference in drug resistance rates when comparing modern Beijing isolates with ancient Beijing isolates (Table 2). In addition, no significant differences were obtained between the drug resistance rates of Bmyc10 and Bmyc25, which accounted for the dominant sub-lineage of modern and ancient Beijing isolates, respectively (Table 2). We tested the relationships between Beijing lineage/modern Beijing sub-lineage and drug resistance. No significant correlation was observed (Beijing lineage, P = 0.326; modern Beijing sub-lineage, P = 0.311).
Table 2. Drug Resistance in Beijing Lineage MTB and Non-Beijing Lineage MTB
Drug Resistance Total N = 331 Beijing (n = 183) non-Beijing (n = 148) Beijing vs. non-Beijing Modern Beijing vs. Ancient Beijing Bmyc10 vs. Bmyc25 Ancient Beijing (n = 72) Modern Beijing (n = 111) Total Total Bmyc25 n = 38 Total Bmyc10 n = 72 χ2 P Values χ2 P Values χ2 P Values INH 35 (10.57%) 8 (11.11%) 6 (15.79%) 18 (16.22%) 10 (13.89%) 26 (14.21%) 9 (6.08%) 5.715 0.017 0.934 0.334 0.072 0.788 EMB 4 (1.21%) 2 (2.78%) 1 (2.63%) 1 (0.90%) 0 (0%) 3 (1.64%) 1 (0.68%) 0.085 0.770 0.145 0.703 a 0.345b RFP 18 (5.44%) 6 (8.33%) 6 (15.79%) 9 (8.11%) 5 (6.94%) 15 (8.20%) 3 (2.03%) 6.057 0.014 0.003 0.957 1.291 0.256a SM 33 (9.97%) 7 (9.72%) 4 (10.53%) 16 (14.41%) 11 (15.28%) 23 (12.57%) 10 (6.76%) 3.079 0.079 0.875 0.350 0.477 0.490 KAM 7 (2.11%) 3 (4.17%) 2 (5.26%) 3 (2.70%) 1 (1.39%) 6 (3.28%) 1 (0.68%) 1.568 0.210a 0.014 0.906 a 0.326 0.568a OFX 27 (8.16%) 4 (5.56%) 3 (7.89%) 14 (12.61%) 8 (11.11%) 18 (9.84%) 9 (6.08%) 1.540 0.215 2.452 0.117 0.040 0.841a CPM 6 (1.81%) 4 (5.56%) 1 (2.63%) 2 (1.80%) 1 (1.39%) 6 (3.28%) 0 (0%) 3.272 0.070 a 0.937 0.333 a 1.000b PTO 1 (0.30%) 0 (0%) 0 (0%) 1 (0.90%) 0 (0%) 1 (0.55%) 0 (0%) 1.000b 1.000b 1.000b PAS 11 (3.32%) 7 (9.72%) 3 (7.89%) 4 (3.60%) 1 (1.39%) 11 (6.01%) 0 (0%) 7.426 0.006 a 1.912 0.167 a 1.435 0.231 a MDR 17 (5.14%) 6 (8.33%) 5 (13.16%) 9 (8.11%) 5 (6.94%) 15 (8.20%) 2 (1.35%) 7.870 0.005 0.003 0.957 0.532 0.466 a Note. INH, isoniazid; RFP, rifampin; EMB, ethambutol; SM, streptomycin; KAN, kanamycin; OFX, ofloxacin; CPM, capreomycin; PAS, para-aminosalicylic acid; PTO, protionamide; a, evaluated with continuity correction chi-square; b, evaluated with Fisher's exact test. -
Based on the VNTR-15 genotyping results combined with drug resistance, as well as SNP genotyping results, we compared the characteristics of a cluster strain versus a unique type strain. The two groups did not differ with respect to drug resistance, lineage, or sub-lineage. The order of the clustering rate of different drug-resistant strains was OFX-resistant, MDR, RFP-resistant, any drug-resistant, INH-resistant, SM-resistant, and PAS-resistant. We tested for associations between clustering rates and the different drug resistant strains. No significant differences in the different drug resistance (except PTO) results were obtained between cluster strains versus unique type strains (P = 0.925; Table 3).
Table 3. Factors Associated with Cluster Strains
Characteristic Cluster Strains (%) Unique Type Strains (%) Cluster vs. Unique Type χ2 P Values Drug resistance 0.925b Yes 9 (17.65%) 42 (82.35%) 0.628 0.428 INH 4 (14.81%) 23 (85.19%) 0.000 1.000a EMB 0 (0%) 3 (100%) 1.000b RFP 3 (21.43%) 11 (78.57%) 0.165 0.685a SM 4 (14.81%) 23 (85.19%) 0.000 1.000a KAM 0 (0%) 4 (100%) 1.000b OFX 6 (30%) 14 (70%) 3.160 0.075a CPM 0 (0%) 4 (100%) 1.000b PTO 0 (0%) 0 (%) 1.000b PAS 1 (12.5%) 7 (87.5%) 0.000 1.000a MDR 3 (23.08%) 10 (76.92%) 0.287 0.592a Lineage 0.123 0.725 Beijing 20 (13.51%) 128 (86.49%) non-Beijing 17 (15.04%) 96 (84.96%) Sublineage 2.241 0.134 Ancient 4 (7.41%) 50 (92.59%) Modern 15 (15.96%) 79 (84.04%) Note. a, evaluated with continuity correction chi-square; b, evaluated with Fisher's exact test. -
To explore the relevance between VNTR genotypes and SNP-defined sub-lineages in our study, we constructed the MST based on VNTR-15 and SNP genotyping results, which was mapped onto the network (Figure 2). In light of the MST map, the Beijing genotype strains in this study were divided into one major complex (shadowed in red). On the whole, the MST for the part of Beijing strains can be divided into three main branches, among which the modern Beijing strains were mainly concentrated on branches Ⅱ and Ⅲ, and the genetic distances among ancient strains were relatively greater than modern Beijing strains. Non-Beijing strains were mainly concentrated on the right of the dotted line, with the exception of three strains (Figure 2). The modern Beijing strains are mainly concentrated in the trunk part of the MST map with a closer genetic distance between each other. The results of VNTR-15 were consistent with the sub-lineage defined by SNP at a lower resolution.
From the dendrogram constructed of VNTR-15 by BioNumerics 5.0 (Figure 3) with the additional SNP-based sub-type information for strains which had both VNTR-15 and 8-loci SNP data [80.88% (148/183)], we found that strains belonging to the same cluster by VNTR were differentiated into different sub-lineages (e.g., cluster Ⅰ contained Bmyc10 and Bmyc13; cluster Ⅱ contained Bmyc10 and Bmyc210; cluster Ⅶ contained Bmyc25 and Bmyc26); however, the other four clusters were composed by the same sub-lineage strains. There were discordances between VNTR-15 and SNP sub-lineages if we set a higher resolution. The SNP genotyping results were a supplement to VNTR-15, which showed a high level of homoplasy.
Figure 3. Dendrogram of VNTR-15 patterns of 148 Beijing strains. The dendrogram was constructed using UPGMA by BioNumeric 5.0. The corresponding isolate ID and sub-lineage were shown alongside the dendrogram on the right.
In addition, we constructed a composite tree based on 8-loci SNP and VNTR-15 to further study the evolution and diversity of each sub-lineage, as previously reported (Figure 4). The skeleton of the composite tree was based on the phylogenetic relationship defined by the SNPs in the 3R gene[27], and each branch was based on the MST of VNTR-15. With the exception of Bmyc6 and Bmyc13, the other six branches of the MST were expressed as a star network structure. This finding is the same as a previous study[8], and the sub-lineages may be caused by the recent funder effect, whereas the VNTR-15 genotype at each MST center is the founder genotype of each sub-lineage. The combination of SNPs and VNTRs can improve the accuracy of epidemiologic analysis of these strains.
doi: 10.3967/bes2018.046
Genetic Diversity and Drug Susceptibility of Mycobacterium tuberculosis Isolates in a Remote Mountain Area of China
-
Abstract:
Objective We determined the genetic diversity of Mycobacterium tuberculosis (MTB) in a remote mountainous area of southwest China and evaluated the resolving ability of single nucleotide polymorphism (SNP) genotyping combined with variable number tandem repeat (VNTR) genotyping for Beijing family strains in association with drug resistance status. Methods Three hundred thirty-one MTB strains were isolated from patients living in mountainous regions of southwest China, and 8-loci SNP, VNTR-15 genotyping assays, and drug susceptibility testing of 9 drugs were performed. Results A total of 183 [55.29% (183/331)] strains were classified into the Beijing family. Of the 183 strains, 111 (60.66%) were defined as modern Beijing strains. The most predominant modern Beijing sub-lineage and ancient Beijing sub-lineage were Bmyc10 [39.34% (72/183)] and Bmyc25 [20.77% (38/183)], respectively. Of the isolates, 19.64% (65/331) were resistant to at least 1 of the 9 anti-TB drugs and 17 [4.98% (17/331)] MTB isolates were multi-drug resistant tuberculosis (MDR-TB). Two hundred sixty-one isolates showed a clustering rate of 14.18% (37/261) and a discriminatory index of 0.9990. The Beijing lineage exhibited a significantly higher prevalence of MDR-TB, as well as resistance to isoniazid (INH), rifampin (RIF), and para-aminosalicylic acid (PAS) when analyzed independently (P=0.005, P=0.017, P=0.014, and P=0.006 respectively). The Beijing lineage was not associated with genetic clustering or resistance to any drug. In addition, genetic clustering was not associated with drug resistance. Conclusion MTB strains demonstrate high genetic diversity in remote mountainous areas of southwest China. Beijing strains, especially modern Beijing strains, are predominant in remote mountainous area of China. The combination of 8-loci SNPs and VNTR-15 genotyping is a useful tool to study the molecular epidemiology of MTB strains in this area. -
Figure 2. Minimal spanning tree of the 261 strains based on VNTR data. Each circle corresponds to a certain VNTR type. The size of the circle is proportional to the number of the isolates. The shadow zones in different colors correspond to different clonal complexes, and the color within the cycles represents different sub-lineages. The dotted line separates Beijing and non-Beijing strains.
Table 1. Distribution of 183 Beijing Strains in Each Sub-lineage (W = wildtype, M = mutant)
Sublineage SNPs No. (%) Subgroup recR (codon 44) mutT4 (codon 48) recX (codon 59) mutT2 (codon 58) uvrD1 (codon 462) adhE2 (codon 124) ligD (codon 580) ogt (codon 37) Bmyc2 W W W W W W M W 10 (5.46) Ancient Bmyc4 M W W W W W W W 10 (5.46) Ancient Bmyc6 M M W W W W W W 6 (3.78) Ancient Bmyc25 M M W W W W W M 38 (20.77) Ancient Bmyc26 M M M W W W W W 8 (4.37) Ancient Bmyc10 M M M M W W W W 72 (39.34) Modern Bmyc13 M M M M M W W W 7 (3.83) Modern Bmyc210 M M M M W M W W 32 (17.49) Modern Table 2. Drug Resistance in Beijing Lineage MTB and Non-Beijing Lineage MTB
Drug Resistance Total N = 331 Beijing (n = 183) non-Beijing (n = 148) Beijing vs. non-Beijing Modern Beijing vs. Ancient Beijing Bmyc10 vs. Bmyc25 Ancient Beijing (n = 72) Modern Beijing (n = 111) Total Total Bmyc25 n = 38 Total Bmyc10 n = 72 χ2 P Values χ2 P Values χ2 P Values INH 35 (10.57%) 8 (11.11%) 6 (15.79%) 18 (16.22%) 10 (13.89%) 26 (14.21%) 9 (6.08%) 5.715 0.017 0.934 0.334 0.072 0.788 EMB 4 (1.21%) 2 (2.78%) 1 (2.63%) 1 (0.90%) 0 (0%) 3 (1.64%) 1 (0.68%) 0.085 0.770 0.145 0.703 a 0.345b RFP 18 (5.44%) 6 (8.33%) 6 (15.79%) 9 (8.11%) 5 (6.94%) 15 (8.20%) 3 (2.03%) 6.057 0.014 0.003 0.957 1.291 0.256a SM 33 (9.97%) 7 (9.72%) 4 (10.53%) 16 (14.41%) 11 (15.28%) 23 (12.57%) 10 (6.76%) 3.079 0.079 0.875 0.350 0.477 0.490 KAM 7 (2.11%) 3 (4.17%) 2 (5.26%) 3 (2.70%) 1 (1.39%) 6 (3.28%) 1 (0.68%) 1.568 0.210a 0.014 0.906 a 0.326 0.568a OFX 27 (8.16%) 4 (5.56%) 3 (7.89%) 14 (12.61%) 8 (11.11%) 18 (9.84%) 9 (6.08%) 1.540 0.215 2.452 0.117 0.040 0.841a CPM 6 (1.81%) 4 (5.56%) 1 (2.63%) 2 (1.80%) 1 (1.39%) 6 (3.28%) 0 (0%) 3.272 0.070 a 0.937 0.333 a 1.000b PTO 1 (0.30%) 0 (0%) 0 (0%) 1 (0.90%) 0 (0%) 1 (0.55%) 0 (0%) 1.000b 1.000b 1.000b PAS 11 (3.32%) 7 (9.72%) 3 (7.89%) 4 (3.60%) 1 (1.39%) 11 (6.01%) 0 (0%) 7.426 0.006 a 1.912 0.167 a 1.435 0.231 a MDR 17 (5.14%) 6 (8.33%) 5 (13.16%) 9 (8.11%) 5 (6.94%) 15 (8.20%) 2 (1.35%) 7.870 0.005 0.003 0.957 0.532 0.466 a Note. INH, isoniazid; RFP, rifampin; EMB, ethambutol; SM, streptomycin; KAN, kanamycin; OFX, ofloxacin; CPM, capreomycin; PAS, para-aminosalicylic acid; PTO, protionamide; a, evaluated with continuity correction chi-square; b, evaluated with Fisher's exact test. Table 3. Factors Associated with Cluster Strains
Characteristic Cluster Strains (%) Unique Type Strains (%) Cluster vs. Unique Type χ2 P Values Drug resistance 0.925b Yes 9 (17.65%) 42 (82.35%) 0.628 0.428 INH 4 (14.81%) 23 (85.19%) 0.000 1.000a EMB 0 (0%) 3 (100%) 1.000b RFP 3 (21.43%) 11 (78.57%) 0.165 0.685a SM 4 (14.81%) 23 (85.19%) 0.000 1.000a KAM 0 (0%) 4 (100%) 1.000b OFX 6 (30%) 14 (70%) 3.160 0.075a CPM 0 (0%) 4 (100%) 1.000b PTO 0 (0%) 0 (%) 1.000b PAS 1 (12.5%) 7 (87.5%) 0.000 1.000a MDR 3 (23.08%) 10 (76.92%) 0.287 0.592a Lineage 0.123 0.725 Beijing 20 (13.51%) 128 (86.49%) non-Beijing 17 (15.04%) 96 (84.96%) Sublineage 2.241 0.134 Ancient 4 (7.41%) 50 (92.59%) Modern 15 (15.96%) 79 (84.04%) Note. a, evaluated with continuity correction chi-square; b, evaluated with Fisher's exact test. -
[1] Frieden TR, Sterling TR, Munsiff SS, et al. Tuberculosis. Lancet, 2003; 362, 887-99. doi: 10.1016/S0140-6736(03)14333-4 [2] World Health Organization. Global tuberculosis report 2017. 2017. [3] du Toit LC, Pillay V, Danckwerts MP. Tuberculosis chemotherapy:current drug delivery approaches. Respir Res, 2006; 7, 118. doi: 10.1186/1465-9921-7-118 [4] Zhao FZ, Murray C, Spinaci S, et al. Results of directly observed short-course chemotherapy in 112, 842 Chinese patients with smear-positive tuberculosis. China Tuberculosis Control Collaboration. Lancet, 1996; 347, 358-62. doi: 10.1016/S0140-6736(96)90537-1 [5] Murray CJ, Salomon JA. Modeling the impact of global tuberculosis control strategies. Proc Natl Acad Sci U S A, 1998; 95, 13881-6. doi: 10.1073/pnas.95.23.13881 [6] Mathema B, Kurepina NE, Bifani PJ, et al. Molecular epidemiology of tuberculosis:current insights. Clin Microbiol Rev, 2006; 19, 658-85. doi: 10.1128/CMR.00061-05 [7] Allix-Beguec C, Harmsen D, Weniger T, et al. Evaluation and strategy for use of MIRU-VNTRplus, a multifunctional database for online analysis of genotyping data and phylogenetic identification of Mycobacterium tuberculosis complex isolates. J Clin Microbiol, 2008; 46, 2692-9. doi: 10.1128/JCM.00540-08 [8] Luo T, Yang C, Gagneux S, et al. Combination of single nucleotide polymorphism and variable-number tandem repeats for genotyping a homogenous population of Mycobacterium tuberculosis Beijing strains in China. J Clin Microbiol, 2012; 50, 633-9. doi: 10.1128/JCM.05539-11 [9] Li QJ, Jiao WW, Yin QQ, et al. Compensatory Mutations of Rifampin Resistance Are Associated with Transmission of Multidrug-Resistant Mycobacterium tuberculosis Beijing Genotype Strains in China. Antimicrob Agents Chemother, 2016; 60, 2807-12. doi: 10.1128/AAC.02358-15 [10] Li D, Dong CB, Cui JY, et al. Dominant modern sublineages and a new modern sublineage of Mycobacterium tuberculosis Beijing family clinical isolates in Heilongjiang Province, China. Infect Genet Evol, 2014; 27, 294-9. doi: 10.1016/j.meegid.2014.08.004 [11] Zheng C, Reynaud Y, Zhao C, et al. New Mycobacterium tuberculosis Beijing clonal complexes in China revealed by phylogenetic and Bayesian population structure analyses of 24-loci MIRU-VNTRs. Sci Rep, 2017; 7, 6065. doi: 10.1038/s41598-017-06346-1 [12] Sun L, Chen X, Zhang W, et al. Mycobacterium tuberculosis Beijing genotype family strain isolated from naturally infected plateau zokor (Myospalax baileyi) in China. Emerg Microbes Infect, 2017; 6, e47. doi: 10.1038/emi.2017.33 [13] Yin QQ, Liu HC, Jiao WW, et al. Evolutionary History and Ongoing Transmission of Phylogenetic Sublineages of Mycobacterium tuberculosis Beijing Genotype in China. Sci Rep, 2016; 6, 34353. doi: 10.1038/srep34353 [14] Yuan L, Huang Y, Mi LG, et al. There is no correlation between sublineages and drug resistance of Mycobacterium tuberculosis Beijing/W lineage clinical isolates in Xinjiang, China. Epidemiol Infect, 2015; 143, 141-9. doi: 10.1017/S0950268814000582 [15] Yin QQ, Jiao WW, Li QJ, et al. Prevalence and molecular characteristics of drug-resistant Mycobacterium tuberculosis in Beijing, China:2006 versus 2012. BMC Microbiol, 2016; 16, 85. doi: 10.1186/s12866-016-0699-2 [16] Saelens JW, Lau-Bonilla D, Moller A, et al. Whole genome sequencing identifies circulating Beijing-lineage Mycobacterium tuberculosis strains in Guatemala and an associated urban outbreak. Tuberculosis (Edinb), 2015; 95, 810-6. doi: 10.1016/j.tube.2015.09.001 [17] Regmi SM, Chaiprasert A, Kulawonganunchai S, et al. Whole genome sequence analysis of multidrug-resistant Mycobacterium tuberculosis Beijing isolates from an outbreak in Thailand. Mol Genet Genomics, 2015; 290, 1933-41. doi: 10.1007/s00438-015-1048-0 [18] Han SJ, Song T, Cho YJ, et al. Complete genome sequence of Mycobacterium tuberculosis K from a Korean high school outbreak, belonging to the Beijing family. Stand Genomic Sci, 2015; 10, 78. doi: 10.1186/s40793-015-0071-4 [19] Coker OO, Regmi SM, Suriyaphol P, et al. Whole-Genome Sequence of a Multidrug-Resistant Mycobacterium tuberculosis Beijing Sequence Type 10 Isolate from an Outbreak in Thailand. Genome Announc, 2014; 2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132623/ [20] Golesi F, Brignatz J, Bellenfant M, et al. Mycobacterium tuberculosis Beijing outbreak in a school in Marseille, France, 2012. Euro Surveill, 2013; 18. doi: 10.2807/ese.18.02.20354-en [21] Chen TC, Lu PL, Yang CJ, et al. Management of a nosocomial outbreak of Mycobacterium tuberculosis Beijing/W genotype in Taiwan:an emphasis on case tracing with high-resolution computed tomography. Jpn J Infect Dis, 2010; 63, 199-203. https://www.researchgate.net/profile/Tun-Chieh_Chen/publication/44623404_Management_of_a_Nosocomial_Outbreak_of_Mycobacterium_tuberculosis_BeijingW_Genotype_in_Taiwan_an_Emphasis_on_Case_Tracing_with_High-Resolution_Computed_Tomography/links/0fcfd5118b5d95423b000000.pdf [22] Affolabi D, Faihun F, Sanoussi N, et al. Possible outbreak of streptomycin-resistant Mycobacterium tuberculosis Beijing in Benin. Emerg Infect Dis, 2009; 15, 1123-5. doi: 10.3201/eid1507.080697 [23] Narvskaya O, Otten T, Limeschenko E, et al. Nosocomial outbreak of multidrug-resistant tuberculosis caused by a strain of Mycobacterium tuberculosis W-Beijing family in St. Petersburg, Russia. Eur J Clin Microbiol Infect Dis, 2002; 21, 596-602. doi: 10.1007/s10096-002-0775-4 [24] European Concerted Action on New Generation Genetic M, Techniques for the E, Control of T. Beijing/W genotype Mycobacterium tuberculosis and drug resistance. Emerg Infect Dis, 2006; 12, 736-43. [25] Wang XH, Ma AG, Han XX, et al. Correlations between drug resistance of Beijing/W lineage clinical isolates of Mycobacterium tuberculosis and sublineages:a 2009-2013 prospective study in Xinjiang province, China. Med Sci Monit, 2015; 21, 1313-8. doi: 10.12659/MSM.892951 [26] Yang C, Luo T, Sun G, et al. Mycobacterium tuberculosis Beijing strains favor transmission but not drug resistance in China. Clin Infect Dis, 2012; 55, 1179-87. doi: 10.1093/cid/cis670 [27] Mestre O, Luo T, Dos Vultos T, et al. Phylogeny of Mycobacterium tuberculosis Beijing strains constructed from polymorphisms in genes involved in DNA replication, recombination and repair. PLoS One, 2011; 6, e16020. doi: 10.1371/journal.pone.0016020 [28] Wang L, Zhang H, Ruan Y, et al. Tuberculosis prevalence in China, 1990-2010; a longitudinal analysis of national survey data. Lancet, 2014; 383, 2057-64. doi: 10.1016/S0140-6736(13)62639-2 [29] Chen L, Pang Y, Ma L, et al. First Insight into the Molecular Epidemiology of Mycobacterium tuberculosis Isolates from the Minority Enclaves of Southwestern China. Biomed Res Int, 2017; 2017, 2505172. https://www.hindawi.com/journals/bmri/2017/2505172/tab1/ [30] Huet G, Constant P, Malaga W, et al. A lipid profile typifies the Beijing strains of Mycobacterium tuberculosis:identification of a mutation responsible for a modification of the structures of phthiocerol dimycocerosates and phenolic glycolipids. J Biol Chem, 2009; 284, 27101-13. doi: 10.1074/jbc.M109.041939 [31] Comas I, Homolka S, Niemann S, et al. Genotyping of genetically monomorphic bacteria:DNA sequencing in Mycobacterium tuberculosis highlights the limitations of current methodologies. PLoS One, 2009; 4, e7815. doi: 10.1371/journal.pone.0007815 [32] Liu Q, Luo T, Dong X, et al. Genetic features of Mycobacterium tuberculosis modern Beijing sublineage. Emerg Microbes Infect, 2016; 5, e14. doi: 10.1038/emi.2016.14 [33] Luo T, Jiang L, Sun W, et al. Multiplex real-time PCR melting curve assay to detect drug-resistant mutations of Mycobacterium tuberculosis. J Clin Microbiol, 2011; 49, 3132-8. doi: 10.1128/JCM.02046-10 [34] Supply P, Allix C, Lesjean S, et al. Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol, 2006; 44, 4498-510. doi: 10.1128/JCM.01392-06 [35] Espinal MA, Laszlo A, Simonsen L, et al. Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med, 2001; 344, 1294-303. doi: 10.1056/NEJM200104263441706 [36] Organization WH. Anti-tuberculosis drug resistance in the world. 2008. [37] Canetti G, Froman S, Grosset J, et al. Mycobacteria:Laboratory Methods for Testing Drug Sensitivity and Resistance. Bull World Health Organ, 1963; 29, 565-78. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2555065/ [38] Grundmann H, Hori S, Tanner G. Determining confidence intervals when measuring genetic diversity and the discriminatory abilities of typing methods for microorganisms. J Clin Microbiol, 2001; 39, 4190-2. doi: 10.1128/JCM.39.11.4190-4192.2001 [39] Hunter PR, Gaston MA. Numerical index of the discriminatory ability of typing systems:an application of Simpson's index of diversity. J Clin Microbiol, 1988; 26, 2465-6. https://www.researchgate.net/profile/Paul_Hunter/publication/239530556_Numerical_IndexoftheDiscriminatory_Ability_ofTypingSystems_an_Application_ofSimpson's_IndexofDiversity/links/0f31752f5684a5f83c000000.pdf [40] Wada T, Iwamoto T, Maeda S. Genetic diversity of the Mycobacterium tuberculosis Beijing family in East Asia revealed through refined population structure analysis. FEMS Microbiol Lett, 2009; 291, 35-43. doi: 10.1111/fml.2009.291.issue-1 [41] Drobniewski F, Balabanova Y, Nikolayevsky V, et al. Drug-resistant tuberculosis, clinical virulence, and the dominance of the Beijing strain family in Russia. JAMA, 2005; 293, 2726-31. doi: 10.1001/jama.293.22.2726 [42] Johnson R, Warren R, Strauss OJ, et al. An outbreak of drug-resistant tuberculosis caused by a Beijing strain in the western Cape, South Africa. Int J Tuberc Lung Dis, 2006; 10, 1412-4. https://www.researchgate.net/publication/6631961_An_outbreak_of_drug-resistant_tuberculosis_caused_by_a_Beijing_strain_in_the_Western_Cape_South_Africa [43] Parwati I, Alisjahbana B, Apriani L, et al. Mycobacterium tuberculosis Beijing genotype is an independent risk factor for tuberculosis treatment failure in Indonesia. J Infect Dis, 2010; 201, 553-7. doi: 10.1086/649522 [44] Parwati I, van Crevel R, van Soolingen D. Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains. Lancet Infect Dis, 2010; 10, 103-11. doi: 10.1016/S1473-3099(09)70330-5 [45] Zhou Y, van den Hof S, Wang S, et al. Association between genotype and drug resistance profiles of Mycobacterium tuberculosis strains circulating in China in a national drug resistance survey. PLoS One, 2017; 12, e0174197. doi: 10.1371/journal.pone.0174197 [46] Liu HC, Deng JP, Dong HY, et al. Molecular Typing Characteristic and Drug Susceptibility Analysis of Mycobacterium tuberculosis Isolates from Zigong, China. Biomed Res Int, 2016; 2016, 6790985. http://www.be-md.ncbi.nlm.nih.gov/pmc/articles/PMC4766316/ [47] Liu Z, Pang Y, Chen S, et al. A First Insight into the Genetic Diversity and Drug Susceptibility Pattern of Mycobacterium tuberculosis Complex in Zhejiang, China. Biomed Res Int, 2016; 2016, 8937539. https://www.researchgate.net/publication/310743916_A_First_Insight_into_the_Genetic_Diversity_and_Drug_Susceptibility_Pattern_of_Mycobacterium_tuberculosis_Complex_in_Zhejiang_China [48] Liu Q, Yang D, Xu W, et al. Molecular typing of Mycobacterium tuberculosis isolates circulating in Jiangsu province, China. BMC Infect Dis, 2011; 11, 288. doi: 10.1186/1471-2334-11-288 [49] Yu Q, Su Y, Lu B, et al. Genetic diversity of Mycobacterium tuberculosis isolates from Inner Mongolia, China. PLoS One, 2013; 8, e57660. doi: 10.1371/journal.pone.0057660 [50] Luo T, Comas I, Luo D, et al. Southern East Asian origin and coexpansion of Mycobacterium tuberculosis Beijing family with Han Chinese. Proc Natl Acad Sci U S A, 2015; 112, 8136-41. doi: 10.1073/pnas.1424063112 [51] Shitikov E, Kolchenko S, Mokrousov I, et al. Evolutionary pathway analysis and unified classification of East Asian lineage of Mycobacterium tuberculosis. Sci Rep, 2017; 7, 9227. doi: 10.1038/s41598-017-10018-5 [52] Yang C, Shen X, Peng Y, et al. Transmission of Mycobacterium tuberculosis in China:a population-based molecular epidemiologic study. Clin Infect Dis, 2015; 61, 219-27. doi: 10.1093/cid/civ255 [53] Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med, 2012; 366, 2161-70. doi: 10.1056/NEJMoa1108789 [54] Supply P, Mazars E, Lesjean S, et al. Variable human minisatellite-like regions in the Mycobacterium tuberculosis genome. Mol Microbiol, 2000; 36, 762-71. https://www.deepdyve.com/lp/wiley/variable-human-minisatellite-like-regions-in-the-mycobacterium-2ZCa1xAcKD [55] Alonso-Rodriguez N, Martinez-Lirola M, Herranz M, et al. Evaluation of the new advanced 15-loci MIRU-VNTR genotyping tool in Mycobacterium tuberculosis molecular epidemiology studies. BMC Microbiol, 2008; 8, 34. doi: 10.1186/1471-2180-8-34 [56] Dong H, Liu Z, Lv B, et al. Spoligotypes of Mycobacterium tuberculosis from different Provinces of China. J Clin Microbiol, 2010; 48, 4102-6. doi: 10.1128/JCM.00549-10